Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Underlying Class | Amount | Exercise Price | Ownership | Footnotes |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
transaction | NGM | Stock Option (Right to Buy) | Award | +50K | 50K | Nov 6, 2023 | Common Stock | 50K | $0.84 | Direct | F1, F2 | |||
transaction | NGM | Stock Option (Right to Buy) | Disposed to Issuer | -50K | -100% | 0 | Nov 6, 2023 | Common Stock | 50K | $29.62 | Direct | F1, F2 | ||
transaction | NGM | Stock Option (Right to Buy) | Award | +35K | 35K | Nov 6, 2023 | Common Stock | 35K | $0.84 | Direct | F2, F3 | |||
transaction | NGM | Stock Option (Right to Buy) | Disposed to Issuer | -35K | -100% | 0 | Nov 6, 2023 | Common Stock | 35K | $15.20 | Direct | F2, F3 | ||
transaction | NGM | Stock Option (Right to Buy) | Award | +17.5K | 17.5K | Nov 6, 2023 | Common Stock | 17.5K | $0.84 | Direct | F2, F4 | |||
transaction | NGM | Stock Option (Right to Buy) | Disposed to Issuer | -17.5K | -100% | 0 | Nov 6, 2023 | Common Stock | 17.5K | $5.36 | Direct | F2, F4 |
Id | Content |
---|---|
F1 | The shares subject to the stock option shall vest over a four-year period commencing March 22, 2021, with 1/4th of the shares vesting on March 22, 2022 and 1/48th of the shares vesting monthly thereafter. |
F2 | Effective November 6, 2023, the Compensation Committee of the Board of Directors of NGM Biopharmaceuticals, Inc. (the "Company") approved a stock option repricing which resulted in, for purposes of Section 16 of the Exchange Act, the cancellation of a previously-granted stock option in exchange for a new stock option having a lower exercise price of $0.84 per share, which is the closing price of the Company's common stock on November 6, 2023. The reduced exercise price is subject to the relevant retention period and other terms outlined in the applicable stock option repricing notice. All of the other terms of the stock option remained unchanged. |
F3 | The shares subject to the stock option vest over a four-year period commencing January 1, 2022, with 1/48th of the shares vesting on a monthly basis. |
F4 | The shares subject to the stock option vest over a two-year period commencing November 4, 2022, with 1/2 of the shares vesting on an annual basis. |